- Home
- MPWR vs ONC Comparison
MPWR vs ONC Comparison
Compare MPWR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPWR
- ONC
- Stock Information
- Founded
- MPWR 1997
- ONC 2010
- Country
- MPWR United States
- ONC Switzerland
- Employees
- MPWR N/A
- ONC N/A
- Industry
- MPWR Semiconductors
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- MPWR Technology
- ONC Health Care
- Exchange
- MPWR Nasdaq
- ONC Nasdaq
- Market Cap
- MPWR 32.6B
- ONC 26.9B
- IPO Year
- MPWR 2004
- ONC N/A
- Fundamental
- Price
- MPWR $738.15
- ONC $250.30
- Analyst Decision
- MPWR Strong Buy
- ONC Strong Buy
- Analyst Count
- MPWR 13
- ONC 9
- Target Price
- MPWR $822.54
- ONC $325.56
- AVG Volume (30 Days)
- MPWR 527.9K
- ONC 345.1K
- Earning Date
- MPWR 07-31-2025
- ONC 08-06-2025
- Dividend Yield
- MPWR 0.85%
- ONC N/A
- EPS Growth
- MPWR 348.37
- ONC N/A
- EPS
- MPWR 37.62
- ONC N/A
- Revenue
- MPWR $2,386,769,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- MPWR $22.97
- ONC $869.15
- Revenue Next Year
- MPWR $15.33
- ONC $19.07
- P/E Ratio
- MPWR $19.57
- ONC N/A
- Revenue Growth
- MPWR 30.57
- ONC 51.16
- 52 Week Low
- MPWR $438.86
- ONC $146.21
- 52 Week High
- MPWR $959.64
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- MPWR 55.44
- ONC N/A
- Support Level
- MPWR $730.00
- ONC N/A
- Resistance Level
- MPWR $778.86
- ONC N/A
- Average True Range (ATR)
- MPWR 24.60
- ONC 0.00
- MACD
- MPWR -1.09
- ONC 0.00
- Stochastic Oscillator
- MPWR 62.05
- ONC 0.00
About MPWR Monolithic Power Systems Inc.
Monolithic Power Systems is an analog and mixed-signal chipmaker, specializing in power management solutions. The firm's mission is to reduce total energy consumption in end systems, and it serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.